Please use this identifier to cite or link to this item:
|Title:||Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia.||Authors:||Schiemann, Anja H
Stowell, Kathryn M
|Issue Date:||Feb-2014||Source:||Anesthesia and analgesia 2014-02; 118(2): 375-80||Abstract:||Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic disorder. More than 300 variants in the ryanodine receptor 1 (RYR1) have been associated with MH; however, only 31 have been identified as causative. To confirm a mutation in RYR1 as being causative for MH, segregation of the potential mutation in at least 2 unrelated families with MH susceptibility must be demonstrated and functional assays must show abnormal calcium release compared with wild-type RYR1. We used "Hot-spot" DNA screening to identify mutations in RYR1 in 3 New Zealand families. B-lymphoblastoid cells were used to compare the amount of calcium released on stimulation with 4-chloro-m-cresol between wild-type RYR1 cells and cells carrying the new variants in RYR1. We identified a known RYR1 mutation (R2355W) in 2 families and another more recently identified (V2354M) mutation in another family. Both mutations segregated with MH susceptibility in the respective families. Cell lines carrying a mutation in RYR1 showed increased sensitivity to 4-chloro-m-cresol. We propose that R2355W is confirmed as being an MH-causative mutation and suggest that V2354M is a RYR1 mutation likely to cause MH.||URI:||http://hdl.handle.net/11055/206||DOI:||10.1213/ANE.0b013e3182a273ea||PubMed URL:||https://www.ncbi.nlm.nih.gov/pubmed/24361844||Journal Title:||Anesthesia and analgesia||Type:||Journal Article
Research Support, Non-U.S. Gov't
|Appears in Collections:||Scholarly and Clinical|
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.